Insider Selling: Janux Therapeutics, Inc. (NASDAQ:JANX) CEO Sells 5,000 Shares of Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell sold 5,000 shares of the business’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $60.00, for a total transaction of $300,000.00. Following the completion of the sale, the chief executive officer now directly owns 293,054 shares in the company, valued at approximately $17,583,240. This represents a 1.68 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

David Alan Campbell also recently made the following trade(s):

• On Tuesday, December 24th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $56.19, for a total transaction of $1,404,750.00.
• On Tuesday, December 3rd, David Alan Campbell sold 15,000 shares of Janux Therapeutics stock. The stock was sold at an average price of $67.00, for a total transaction of $1,005,000.00.
• On Monday, November 25th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $51.60, for a total transaction of $1,290,000.00.
• On Monday, October 28th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The stock was sold at an average price of $53.54, for a total transaction of $1,338,500.00.

Janux Therapeutics Stock Performance

Shares of JANX stock traded down $6.99 on Wednesday, hitting $50.82. The company’s stock had a trading volume of 2,261,422 shares, compared to its average volume of 1,402,304. Janux Therapeutics, Inc. has a fifty-two week low of $7.79 and a fifty-two week high of $71.71. The company has a market capitalization of $2.67 billion, a PE ratio of -43.44 and a beta of 3.23. The stock’s 50 day moving average is $54.48 and its 200-day moving average is $48.16.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The business had revenue of $0.44 million during the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics’s quarterly revenue was down 82.6% on a year-over-year basis. On average, research analysts forecast that Janux Therapeutics, Inc. will post -1.35 earnings per share for the current year.

Hedge Funds Weigh In On Janux Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. FMR LLC lifted its holdings in shares of Janux Therapeutics by 0.6% during the 3rd quarter. FMR LLC now owns 7,824,675 shares of the company’s stock worth $355,475,000 after acquiring an additional 47,075 shares during the period. Janus Henderson Group PLC lifted its stake in Janux Therapeutics by 40.0% during the third quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock worth $114,587,000 after purchasing an additional 721,563 shares during the last quarter. Logos Global Management LP boosted its holdings in shares of Janux Therapeutics by 400.0% in the 2nd quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock valued at $31,418,000 after purchasing an additional 600,000 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Janux Therapeutics by 6.2% in the 3rd quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock valued at $30,107,000 after purchasing an additional 38,490 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its stake in shares of Janux Therapeutics by 190.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 395,875 shares of the company’s stock valued at $17,985,000 after purchasing an additional 259,445 shares during the last quarter. Institutional investors own 75.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on JANX shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $200.00 price target on shares of Janux Therapeutics in a report on Wednesday, December 11th. Lifesci Capital upgraded Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. HC Wainwright boosted their target price on Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a research note on Tuesday, December 3rd. Finally, BTIG Research lifted their price objective on shares of Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $89.90.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.